ACvac1 / Axon Neurosci - LARVOL DELTA

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. (PubMed, EBioMedicine) - "The virus-neutralizing properties were fully reproduced in chimeric mouse-human versions of the antibodies, which may represent a promising tool for COVID-19 therapy."

Journal • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

Axon Neuroscience to launch world's first crowdfunded vaccine against COVID-19 (PRNewswire) - "Investment opportunities beginning in October 2020; Plan to enter phase I clinical trials in the fourth quarter 2020; AXON Neuroscience...is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1....ACvac1 induced extensive antibody production in vaccinated mice, effectively blocking the live virus from replicating..."

New P1 trial • Preclinical • Infectious Disease • Novel Coronavirus Disease